Celator Pharms Drug Patent Portfolio
Celator Pharms owns 1 orange book drug protected by 9 US patents Given below is the list of Celator Pharms's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10028912 | Method of lyophilizing liposomes | 15 Oct, 2032 | Active |
| US10166184 | Method of lyophilizing liposomes | 15 Oct, 2032 | Active |
| US10835492 | Method of lyophilizing liposomes | 15 Oct, 2032 | Active |
| US8092828 | Fixed drug ratios for treatment of hematopoietic cancers and proliferative disorders | 01 Apr, 2029 | Active |
| US8022279 | Liposomal formulations of anthracycline agents and cytidine analogs | 14 Sep, 2027 | Active |
| US7850990 | Compositions for delivery of drug combinations | 23 Jan, 2027 | Active |
| US9271931 | Compositions for delivery of drug combinations | 23 Jan, 2027 | Active |
| US8518437 | Lipid carrier compositions with enhanced blood stability | 07 Jun, 2026 | Active |
| US8431806 | Liposomal formulations of anthracycline agents and cytidine analogs | 22 Apr, 2025 | Active |
Latest Legal Activities on Celator Pharms's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Celator Pharms.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 01 May, 2024 | US10835492 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 28 Jun, 2023 | US8092828 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 08 Mar, 2023 | US8022279 |
|
Correspondence Address Change
Critical
| 07 Mar, 2023 | US8518437 |
|
Correspondence Address Change
Critical
| 27 Feb, 2023 | US8092828 |
|
Correspondence Address Change
Critical
| 27 Feb, 2023 | US8431806 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 03 Jan, 2023 | US8431806 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 03 Jan, 2023 | US8092828 |
|
Email Notification
Critical
| 03 Jan, 2023 | US8431806 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 03 Jan, 2023 | US10028912 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 03 Jan, 2023 | US10166184 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 03 Jan, 2023 | US10835492 |
|
Email Notification
Critical
| 03 Jan, 2023 | US8092828 |
|
Email Notification
Critical
| 03 Jan, 2023 | US10028912 |
|
Email Notification
Critical
| 03 Jan, 2023 | US10166184 |
Celator Pharms's Drug Patent Litigations
Celator Pharms's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Dec 06, 2010, against patent number US8518437. The petitioner , challenged the validity of this patent, with Paul Tardi et al as the respondent. Click below to track the latest information on how companies are challenging Celator Pharms's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US9271931 | October, 2012 |
Decision
(31 Aug, 2015)
| Paul Tardi et al | |
| US8518437 | December, 2010 |
Decision
(05 Mar, 2013)
| Paul Tardi et al | |
Celator Pharms Drug Patents' Oppositions Filed in EPO
Celator Pharms drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Aug 15, 2018, by Teva Pharmaceutical Industries Ltd. This opposition was filed on patent number EP08730048A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
| | |||
| EP17200498A | Oct, 2022 | Generics [UK] Limited | Granted and Under Opposition |
| EP17200498A | Oct, 2022 | SANDOZ AG | Granted and Under Opposition |
| EP17200498A | Oct, 2022 | STADA Arzneimittel AG | Granted and Under Opposition |
| EP12841616A | Apr, 2020 | D Young & Co LLP | Granted and Under Opposition |
| EP12841616A | Apr, 2020 | SANDOZ AG | Granted and Under Opposition |
| EP08730048A | Aug, 2018 | Generics (U.K.) Limited | Revoked |
| EP08730048A | Aug, 2018 | Teva Pharmaceutical Industries Ltd | Revoked |
Celator Pharms's Family Patents
Celator Pharms Drug List
Given below is the complete list of Celator Pharms's drugs and the patents protecting them.
1. Vyxeos
Vyxeos is protected by 9 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10028912 | Method of lyophilizing liposomes |
15 Oct, 2032
(7 years from now)
| Active |
| US10166184 | Method of lyophilizing liposomes |
15 Oct, 2032
(7 years from now)
| Active |
| US10835492 | Method of lyophilizing liposomes |
15 Oct, 2032
(7 years from now)
| Active |
| US8092828 | Fixed drug ratios for treatment of hematopoietic cancers and proliferative disorders |
01 Apr, 2029
(4 years from now)
| Active |
| US8022279 | Liposomal formulations of anthracycline agents and cytidine analogs |
14 Sep, 2027
(2 years from now)
| Active |
| US7850990 | Compositions for delivery of drug combinations |
23 Jan, 2027
(2 years from now)
| Active |
| US9271931 | Compositions for delivery of drug combinations |
23 Jan, 2027
(2 years from now)
| Active |
| US8518437 | Lipid carrier compositions with enhanced blood stability |
07 Jun, 2026
(1 year, 6 months from now)
| Active |
| US8431806 | Liposomal formulations of anthracycline agents and cytidine analogs |
22 Apr, 2025
(5 months from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Vyxeos's drug page